NMRA Earnings Neumora Therapeutics, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing
Annual results
EPS
Net income
ROE
Quarterly results
EPS
Net income
ROE
Reported EPS history
1–19 of 19
| Q2 2026 | 2026-06-30 | -0.23 | 2026-08-14 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.30 | 2026-05-07 | 10-Q |
| Q4 2025 (derived) | 2025-12-31 | -0.35 | 2026-03-30 | 10-K |
| FY 2025 | 2025-12-31 | -1.45 | 2026-03-30 | 10-K |
| Q3 2025 | 2025-09-30 | -0.35 | 2025-11-06 | 10-Q |
| Q2 2025 | 2025-06-30 | -0.33 | 2025-08-06 | 10-Q |
| Q1 2025 | 2025-03-31 | -0.42 | 2025-05-12 | 10-Q |
| Q4 2024 (derived) | 2024-12-31 | -0.37 | 2025-03-03 | 10-K |
| FY 2024 | 2024-12-31 | -1.53 | 2025-03-03 | 10-K |
| Q3 2024 | 2024-09-30 | -0.45 | 2024-11-12 | 10-Q |
| Q2 2024 | 2024-06-30 | -0.37 | 2024-08-06 | 10-Q |
| Q1 2024 | 2024-03-31 | -0.34 | 2024-05-07 | 10-Q |
| Q4 2023 (derived) | 2023-12-31 | 0.01 | 2024-03-07 | 10-K |
| FY 2023 | 2023-12-31 | -3.63 | 2024-03-07 | 10-K |
| Q3 2023 | 2023-09-30 | -1.14 | 2023-11-01 | 10-Q |
| Q2 2023 | 2023-06-30 | -1.28 | — | — |
| Q1 2023 | 2023-03-31 | -1.22 | — | — |
| FY 2022 | 2022-12-31 | -4.81 | — | — |
| Q3 2022 | 2022-09-30 | -1.06 | — | — |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.